PRE
Prenetics Global Limited16.58
+1.95+13.3%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Subs boost AOV; new SKUs timed
Q&A unpacked IM8's quarterly subscription shift—launched December in the US—which doubled new customer AOV to $233 from $110, slashed logistics costs, and shortens payback via upfront payments. Executives timed two new health supplements for Q4 2026 in $500M-$1B TAMs, explicitly excluded from the $180M-$200M revenue guide. CAC scales proportionally without hikes; AI fuels 800 weekly ad variants and Q2 localizations eyeing 10-15% international uplifts. Organic build leads over M&A. Early 2026 momentum persists. Investors track retention and scale economics.
Key Stats
Market Cap
279.02MP/E (TTM)
-Basic EPS (TTM)
-3.59Dividend Yield
0%IPO
Website
Employees
Sector
Industry
APDN
Applied DNA Sciences, Inc.
5.62+1.35
GNTLF
GENETIC TECHNOLOGIES
1.00+0.00
IDXG
Interpace Biosciences, Inc.
1.14-0.02
ILMN
Illumina, Inc.
131.56-3.36
LDDD
LONGDUODUO CO LTD.
0.59+0.00
MEHCQ
CHROME HLDG CO
3.50+0.00
PRPH
ProPhase Labs, Inc.
0.12+0.00
PRPO
Precipio, Inc.
24.02-0.04
PSNL
Personalis, Inc.
7.98-0.50
WGS
GeneDx Holdings Corp.
141.72-8.89